DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Agenerase (Amprenavir) - Side Effects and Adverse Reactions

 
 



ADVERSE REACTIONS

In clinical studies, adverse events leading to amprenavir discontinuation occurred primarily during the first 12 weeks of therapy, and were mostly due to gastrointestinal events (nausea, vomiting, diarrhea, and abdominal pain/discomfort), which were mild to moderate in severity.

Skin rash occurred in 22% of patients treated with amprenavir in studies PROAB3001 and PROAB3006. Rashes were usually maculopapular and of mild or moderate intensity, some with pruritus. Rashes had a median onset of 11 days after amprenavir initiation and a median duration of 10 days. Skin rashes led to amprenavir discontinuation in approximately 3% of patients. In some patients with mild or moderate rash, amprenavir dosing was often continued without interruption; if interrupted, reintroduction of amprenavir generally did not result in rash recurrence.

Severe or life-threatening rash (Grade 3 or 4), including cases of Stevens-Johnson syndrome, occurred in approximately 1% of recipients of AGENERASE (see WARNINGS). Amprenavir therapy should be discontinued for severe or life-threatening rashes and for moderate rashes accompanied by systemic symptoms.

Table 9. Selected Clinical Adverse Events of All Grades Reported in >5% of Adult Patients

Adverse Event

PROAB3001

Therapy-Naive Patients

PROAB3006

NRTI-Experienced Patients

AGENERASE/Lamivudine/

Zidovudine

(n = 113)

Lamivudine/

Zidovudine

(n = 109)

AGENERASE/NRTI

(n = 245)

Indinavir/

NRTI

(n = 241)

Digestive

Nausea

74%

50%

43%

35%

Vomiting

34%

17%

24%

20%

Diarrhea or loose stools

39%

35%

60%

41%

Taste disorders

10%

6%

2%

8%

Skin

Rash

27%

6%

20%

15%

Nervous

Paresthesia, oral/perioral

26%

6%

31%

2%

Paresthesia, peripheral

10%

4%

14%

10%

Psychiatric

Depressive or mood disorders

16%

4%

9%

13%

Among amprenavir-treated patients in Phase 3 studies, 2 patients developed de novo diabetes mellitus, 1 patient developed a dorsocervical fat enlargement (buffalo hump), and 9 patients developed fat redistribution.

In studies PROAB3001 and PROAB3006, no increased frequency of Grade 3 or 4 AST, ALT, amylase, or bilirubin elevations was seen compared to controls.

Pediatric Patients

An adverse event profile similar to that seen in adults was seen in pediatric patients.

Concomitant Therapy with Ritonavir

Tables 10 and 11 present adverse clinical events and laboratory abnormalities observed in subjects who received AGENERASE plus ritonavir. Since the trials were small, open-label, of varying duration, and often included different patient populations, direct comparisons to the frequency of events with AGENERASE alone (see Table 9) cannot be made.

Table 10. Selected Clinical Adverse Events of All Grades Reported in Adult Patients in Open-Label Clinical Trials of AGENERASE in Combination With Ritonavir

Adverse Event

AGENERASE 1,200 mg plus Ritonavir 200 mg q.d.* (n = 101)

AGENERASE 600 mg

plus Ritonavir 100 mg b.i.d.

(n = 239)

Nausea

31%

23%

Diarrhea/loose stools

30%

28%

Headache

16%

12%

Abdominal symptoms

14%

14%

Vomiting

11%

9%

Rash

10%

9%

Paresthesias

9%

11%

Fatigue

7%

14%

Depressive & mood disorders

4%

9%

* Data from 2 open-label studies in treatment-naive patients also receiving abacavir/lamivudine.

Data from 3 open-label studies in treatment-naive and treatment-experienced patients receiving combination antiretroviral therapy.

Table 11. Grade 3/4 Laboratory Abnormalities Reported in ≥2% of Adult Patients in Open-Label Clinical Trials of AGENERASE in Combination With Ritonavir

Laboratory Abnormality

(non-fasting specimens)

AGENERASE 1,200 mg plus Ritonavir 200 mg q.d.*

(n = 101)

AGENERASE 600 mg

plus Ritonavir 100 mg b.i.d.

(n = 239)

Hypertriglyceridemia (>750 mg/dL)

8%

13%

Hyperglycemia (>251 mg/dL)

2%

3%

AST (>5 x ULN)

3%

5%

ALT (>5 x ULN)

4%

4%

Amylase (>2 x ULN)

4%

3%

* Data from 2 open-label studies in treatment-naive patients also receiving abacavir/lamivudine.

Data from 3 open-label studies in treatment-naive and treatment-experienced patients receiving combination antiretroviral therapy.



REPORTS OF SUSPECTED AGENERASE SIDE EFFECTS / ADVERSE REACTIONS

Below is a sample of reports where side effects / adverse reactions may be related to Agenerase. The information is not vetted and should not be considered as verified clinical evidence.

Possible Agenerase side effects / adverse reactions in 41 year old male

Reported by a consumer/non-health professional from Canada on 2012-02-15

Patient: 41 year old male

Reactions: Confusional State, Fatigue, Headache

Suspect drug(s):
Agenerase

Intelence

Lamivudine

Tipranavir + Ritonavir CO-Admin

Sustiva

Videx EC



See index of all Agenerase side effect reports >>

Drug label data at the top of this Page last updated: 2006-06-19

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017